Literature DB >> 16022836

[Prevalence of neuropathic pain in Spain: clinical, working and health care implications].

Rafael Gálvez1, Javier Rejas, María Pérez, Margarita Gómez.   

Abstract

A narrative systematic medical literature review on prevalence of neuropathic pain (NP) in Spain from 1990 to 2004 was conducted. The average number of publications was 3 per year. Prevalence data varied depending on studied population, definition of pain/pathology and time of pain evolution. The most commonly studied pathologies included: mononeuropathies and polyneuropathies: 42%, multiple sclerosis: 35% and entrapment neuropathies: 16%. Some episodes of NP were left untreated. One third of patients with back pain receiving analgesic treatment still had high intensity pain. Future studies on the prevalence of NP should use work definitions and criteria reached by consensus. An awareness of the clinical presentation of NP and an appropriate and early treatment could minimize its clinical, working and health care implications. NP is a diverse and highly prevalent condition in Spain. Efforts should be conducted towards the achievement of diagnostic criteria consensus and higher rates of analgesic success.

Entities:  

Mesh:

Year:  2005        PMID: 16022836     DOI: 10.1157/13077380

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN: 0025-7753            Impact factor:   1.725


  7 in total

1.  The prevalence of neuropathic pain: clinical evaluation compared with screening tools in a community population.

Authors:  Barbara P Yawn; Peter C Wollan; Toby N Weingarten; James C Watson; W Michael Hooten; L Joseph Melton
Journal:  Pain Med       Date:  2009-03-17       Impact factor: 3.750

2.  A cost-consequence analysis of pregabalin versus usual care in the symptomatic treatment of refractory low back pain: sub-analysis of observational trial data from orthopaedic surgery and rehabilitation clinics.

Authors:  Carles Morera-Domínguez; Félix Ceberio-Balda; Mariano Flórez-García; Xavier Masramón; Vanessa López-Gómez
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

3.  Prevalence and characterization of neuropathic pain in a primary-care setting in Spain: a cross-sectional, multicentre, observational study.

Authors:  Concepción Pérez; María Teresa Saldaña; Ana Navarro; Inma Vilardaga; Javier Rejas
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

4.  Validity and reliability of the Spanish version of the DN4 (Douleur Neuropathique 4 questions) questionnaire for differential diagnosis of pain syndromes associated to a neuropathic or somatic component.

Authors:  Concepcion Perez; Rafael Galvez; Silvia Huelbes; Joaquin Insausti; Didier Bouhassira; Silvia Diaz; Javier Rejas
Journal:  Health Qual Life Outcomes       Date:  2007-12-04       Impact factor: 3.186

5.  Cost of treatment of peripheral neuropathic pain with pregabalin or gabapentin in routine clinical practice: impact of their loss of exclusivity.

Authors:  Antoni Sicras-Mainar; Javier Rejas-Gutiérrez; María Pérez-Páramo; Ruth Navarro-Artieda
Journal:  J Eval Clin Pract       Date:  2016-09-27       Impact factor: 2.431

6.  Evaluation of Quality of Life and Satisfaction of Patients with Neuropathic Pain and Breakthrough Pain: Economic Impact Based on Quality of Life.

Authors:  María Candelas Madariaga Muñoz; Francisco Villegas Estévez; Antonio Javier Jiménez López; Ana Cabezón Álvarez; Begoña Soler López
Journal:  Pain Res Treat       Date:  2018-09-05

Review 7.  In Vitro and In Vivo Effects of Flavonoids on Peripheral Neuropathic Pain.

Authors:  Paramita Basu; Arpita Basu
Journal:  Molecules       Date:  2020-03-05       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.